• Cardiac diseases in women associated with pregnancy
en To content Full text of article

Cardiac diseases in women associated with pregnancy

PERINATOLOGY AND PEDIATRIC. UKRAINE. 2018.4(76):33-37; doi 10.15574/PP.2018.76.33

Davydova Iu. V., Dubrov S. A., Siromaha S. O., Limanskaya A. Yu., Ogorodnyk A. A., Rudenko K. V., Butenko L. P., Chyzhevskaya Е. A.
SI «Institute of Pediatrics, Obstetrics and Gynecology named of academician O.M. Lukyanova NAMS of Ukraine», Kyiv
SI «Amosov National Institute of Cardiovascular Surgery of NAMS of Ukraine», Kyiv

The article presents data on modern views on the mechanisms of development of peripartum cardiomyopathy (PPCM), presents an diagnostic algorithm, as well as a schedule for the treatment of PPCM. PPCM — non-familial idiopathic cardiomyopathy, manifested by heart failure, secondary to left ventricular systolic dysfunction, at the end of pregnancy or in the first months after birth, if there are no other proved causes of heart failure. There is a tendency to an increase in the frequency of PPCM, for example, in the United States in 1993, its frequency was 1:4350 births, and in 2002, 1:2229. Given the urgency of the problem consider modern diagnostic markers for PPCM, such as NTproBNP, Katepsin D, Prolactin 16 kDa, Asymmetric dimethylarginine, sFlT-1, microRNA-146a, Interferon-gamma. The clinical cases of PPCM during pregnancy and in the postpartum period are given. Conclusions are drawn about the expediency of a multidisciplinary approach, careful monitoring patients with the inclusion of instrumental and laboratory methods disease control.

Key words: peripartum cardiomyopathy, diagnostics, treatment, biomarkers.


1. Bauersachs J. (2017). Poor outcomes in poor patients?: Peripartum cardiomyopathy-not just Black and White. JAMA Cardiol. 2: 1261–1262. https://doi.org/10.1001/jamacardio.2017.3605; PMid:29049487

2. Bauersachs J, Arrigo M, Hilfiker–Kleiner D, Veltmann C et al. (2016). Current management of patients with severe acute peripartum cardiomyopathy: practical guidance from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy. Eur J Heart Fail. 18: 1096–1105. https://doi.org/10.1002/ejhf.586; PMid:27338866

3. Benlolo S, Lefoll C, Katchatouryan V, Payen D, Mebazaa A. (2004). Successful use of levosimendan in a patient with peripartum cardiomyopathy. AnesthAnalg. 98: 822–824. https://doi.org/10.1213/01.ANE.0000099717.40471.83; PMid:14980944

4. Haghikia A, Podewski E, Libhaber E et al. (2013). Phenotyping and outcome on contemporary management in a German cohort of patients with peripartum cardiomyopathy. Basic Res Cardiol. 108: 366. https://doi.org/10.1007/s00395-013-0366-9; PMid:23812247 PMCid:PMC3709080

5. Halkein J, Tabruyn SP, Ricke–Hoch M et al. (2013). MicroRNA-146a is a therapeutic target and biomarker for peripartum cardiomyopathy. J Clin Invest. 123: 2143–2154. https://doi.org/10.1172/JCI64365; PMid:23619365

6. Hilfiker–Kleiner D, Haghikia A, Nonhoff J, Bauersachs J. (2015). Peripartum cardiomyopathy: current management and future perspectives. Eur Heart J. 36: 1090–1097. https://doi.org/10.1093/eurheartj/ehv009; PMid:25636745

7. Hilfiker–Kleiner D, Haghikia A, Berliner D et al. (2017). Bromocriptine for the treatment of peripartum cardiomyopathy: a multicentrerandomised study. Eur Heart J. 38: 2671–2679. https://doi.org/10.1093/eurheartj/ehx355; PMid:28934837

8. McNamara DM, Elkayam U, Alharethi R et al. (2015). Clinical outcomes for peripartum cardiomyopathy in North America: Results of the IPAC study (Investigations of Pregnancy–Associated Cardiomyopathy). J Am Coll Cardiol. 66: 905–914. https://doi.org/10.1016/j.jacc.2015.06.1309; PMid:26293760

9. Patten IS, Rana S, Shahul S et al. (2012). Cardiac angiogenic imbalance leads to peripartum cardiomyopathy. Nature. 485: 333–338. https://doi.org/10.1038/nature11040; PMid:22596155

10. Sliwa K, Fett J, Elkayam U. (2006). Peripartum cardiomyopathy. Lancet. 368: 687–693. https://doi.org/10.1016/S0140-6736(06)69253-2

11. Sliwa K, Boehm M. (2014). Incidence and prevalence of pregnancy associated heart disease. Cardiovasc Res. 101: 554–560. https://doi.org/10.1093/cvr/cvu012; PMid:24459193

12. Ware JS, Li J, Mazaika E et al. (2016). Shared Genetic Predisposition in Peripartum and Dilated Cardiomyopathies. N Engl J Med. 374: 233–241. https://doi.org/10.1056/NEJMoa1505517; PMid:26735901

Article received: Aug 29, 2018. Accepted for publication: Dec 18, 2018.